RVL Pharmaceuticals plc (NASDAQ:RVLP) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET

Company Participants

Lisa Wilson – Investor Relations

Brian Markison – Chief Executive Officer

Mike DePetris – Interim Chief Financial Officer

JD Schaub – Chief Operational Officer

Conference Call Participants

Douglas Tsao – H.C Wainwright

Louise Chen – Cantor

Greg Fraser – Truist Securities

Balaji Prasad – Barclays

Operator

Good morning everyone. My name is Bertney and I will be your conference operator. At this time I like to welcome everyone to the RVL Pharmaceuticals First Quarter 2022 Financial Results Call. All lines have been placed on mute prevent any background noise. After the speakers’ remarks, there will be a question-and-answer period. [Operator Instructions]

Lisa Wilson

Thank you, operator. Welcome to RVL Pharmaceuticals, first quarter 2022 financial results and commercial update call. This is Lisa Wilson, Investor Relations for RVL.

With me on today's call are RVL’s Chief Executive Officer, Brian Markison; Chief Operational Officer, JD Schaub; and Interim Chief Financial Officer, Mike DePetris.

This morning, the company issued a press release detailing financial results for the three months ended March 31, 2021. This press release and a webcast of this call can be accessed through the Investors section of the RVL website at rvlpharma.com.

Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events, and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act.

These forward-looking statements are based upon information available to RVL's management as of today, and involve risks and uncertainties, including those noted in the press release and our filings with the Securities and Exchange Commission. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law.

During this call, we may refer to non-GAAP financial measures such as adjusted EBITDA. For a reconciliation of adjusted EBITDA to net income or loss from continuing operations, please see the tables at the end of today’s press release. The archived webcast of this call will be available for one year on RVL’s website, rvlpharma.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on Thursday, May 12 2022. Since then RVL may have made announcements related to the topics discussed, so please reference to company's most recent press releases and SEC filings.